Nigel S. Bamford,1,2,3,* Hui Zhang,4 John A. Joyce,1 Christine A. Scarlis,1 Whitney Hanan,1 Nan-Ping Wu,5 Ve´ ronique M. Andre´ ,5 Rachel Cohen,5 Carlos Cepeda,5 Michael S. Levine,5 Erin Harleton,4 and David Sulzer4,6,7
1Department of Neurology 2Center on Human Development and Disability
University of Washington, Seattle, WA 98105, USA 3Department of Pediatrics and Psychology, University of Washington and Children’s Hospital and Regional Medical Center, Seattle, WA 98105, USA
4Departments of Neurology, Psychiatry, and Pharmacology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
5Mental Retardation Research Center, The David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA 6Center for Neurobiology and Behavior, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA 7Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA *Correspondence: bamford@u.washington.edu
DOI 10.1016/j.neuron.2008.01.033

Richard A. Rawson, (Ph.D.)a,., Rachel Gonzales, (Ph.D.)a, Valerie Pearce, (M.P.H.)a, Alfonso Ang, (Ph.D.)b, Patricia Marinelli-Casey, (Ph.D.)a, Julie Brummer, (B.A.)a Methamphetamine Treatment Project Corporate Authors